Literature DB >> 19155526

A novel antiangiogenic effect for telomerase-specific virotherapy through host immune system.

Yoshihiro Ikeda1, Toru Kojima, Shinji Kuroda, Yoshikatsu Endo, Ryo Sakai, Masayoshi Hioki, Hiroyuki Kishimoto, Futoshi Uno, Shunsuke Kagawa, Yuichi Watanabe, Yuuri Hashimoto, Yasuo Urata, Noriaki Tanaka, Toshiyoshi Fujiwara.   

Abstract

Soluble factors in the tumor microenvironment may influence the process of angiogenesis; a process essential for the growth and progression of malignant tumors. In this study, we describe a novel antiangiogenic effect of conditional replication-selective adenovirus through the stimulation of host immune reaction. An attenuated adenovirus (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E1 genes, could replicate in and cause selective lysis of cancer cells. Mixed lymphocyte-tumor cell culture demonstrated that OBP-301-infected cancer cells stimulated PBMC to produce IFN-gamma into the supernatants. When the supernatants were subjected to the assay of in vitro angiogenesis, the tube formation of HUVECs was inhibited more efficiently than recombinant IFN-gamma. Moreover, in vivo angiogenic assay using a membrane-diffusion chamber system s.c. transplanted in nu/nu mice showed that tumor cell-induced neovascularization was markedly reduced when the chambers contained the mixed lymphocyte-tumor cell culture supernatants. The growth of s.c. murine colon tumors in syngenic mice was significantly inhibited due to the reduced vascularity by intratumoral injection of OBP-301. The antitumor as well as antiangiogenic effects, however, were less apparent in SCID mice due to the lack of host immune responses. Our data suggest that OBP-301 seems to have antiangiogenic properties through the stimulation of host immune cells to produce endogenous antiangiogenic factors such as IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155526     DOI: 10.4049/jimmunol.182.3.1763

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Impact of tumor microenvironment on oncolytic viral therapy.

Authors:  Jeffrey Wojton; Balveen Kaur
Journal:  Cytokine Growth Factor Rev       Date:  2010 Apr-Jun       Impact factor: 7.638

Review 2.  Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.

Authors:  Lihong Wang; Louisa S Chard Dunmall; Zhenguo Cheng; Yaohe Wang
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

3.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

Review 4.  Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.

Authors:  Peter Kok-Ting Wan; Anderson J Ryan; Leonard W Seymour
Journal:  Mol Ther       Date:  2021-04-19       Impact factor: 11.454

5.  The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.

Authors:  Carmela Passaro; Francesco Borriello; Viviana Vastolo; Sarah Di Somma; Eloise Scamardella; Vincenzo Gigantino; Renato Franco; Gianni Marone; Giuseppe Portella
Journal:  Oncotarget       Date:  2016-01-12

6.  Tumor-specific delivery of biologics by a novel T-cell line HOZOT.

Authors:  Teppei Onishi; Hiroshi Tazawa; Yuuri Hashimoto; Makoto Takeuchi; Takeshi Otani; Shuji Nakamura; Fuminori Sakurai; Hiroyuki Mizuguchi; Hiroyuki Kishimoto; Yuzo Umeda; Yasuhiro Shirakawa; Yasuo Urata; Shunsuke Kagawa; Toshiyoshi Fujiwara
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

Review 7.  Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?

Authors:  Victor A Naumenko; Aleksei A Stepanenko; Anastasiia V Lipatova; Daniil A Vishnevskiy; Vladimir P Chekhonin
Journal:  Mol Ther Oncolytics       Date:  2022-02-12       Impact factor: 7.200

8.  Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.

Authors:  Kseniya S Yurchenko; Alexandra V Glushchenko; Marina A Gulyaeva; Yuhai Bi; Jianjun Chen; Weifeng Shi; Lyubov S Adamenko; Alexander M Shestopalov
Journal:  Viruses       Date:  2021-03-25       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.